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Abstract
Background: Nocturnal gastroesophageal reflux (nGER) is associated with respiratory symptoms and sleep-disordered
breathing (SDB), but the pathogenesis is unclear. We aimed to investigate the association between nGER and
respiratory symptoms, exacerbations of respiratory symptoms, SDB and airway inflammation.
Methods: Participants in the European Community Respiratory Health Survey III in Iceland with nGER
symptoms (n = 48) and age and gender matched controls (n = 42) were studied by questionnaires, exhaled
breath condensate (EBC), particles in exhaled air (PEx) measurements, and a home polygraphic study. An
exacerbation of respiratory symptoms was defined as an episode of markedly worse respiratory symptoms in
the previous 12 months.
Results: Asthma and bronchitis symptoms were more common among nGER subjects than controls (54 % vs
29 %, p = 0.01; and 60 % vs 26 %, p < 0.01, respectively), as were exacerbations of respiratory symptoms (19 %
vs 5 %, p = 0.04). Objectively measured snoring was more common among subjects with nGER than controls
(snores per hour of sleep, median (IQR): 177 (79–281) vs 67 (32–182), p = 0.004). Pepsin (2.5 ng/ml (0.8–5.8) vs
0.8 ng/ml (0.8–3.6), p = 0.03), substance P (741 pg/ml (626–821) vs 623 pg/ml (562–676), p < 0.001) and
8-isoprostane (3.0 pg/ml (2.7–3.9) vs 2.6 pg/ml (2.2–2.9), p = 0.002) in EBC were higher among nGER subjects
than controls. Albumin and surfactant protein A in PEx were lower among nGER subjects. These findings were
independent of BMI.
Conclusion: In a general population sample, nGER is associated with symptoms of asthma and bronchitis, as
well as exacerbations of respiratory symptoms. Also, nGER is associated with increased respiratory effort during
sleep. Biomarker measurements in EBC, PEx and serum indicate that micro-aspiration and neurogenic
inflammation are plausible mechanisms.
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Background
Gastroesophageal reflux (GER), and especially nocturnal
GER (nGER), is associated with many symptoms from
the respiratory tract, often asthma symptoms [1–3].
However, it is not fully known how GER patients with
asthma symptoms differ from other asthma patients,
and what the pathogenic mechanisms are.
Sleep-disordered breathing (SDB) and nGER are also
closely linked. The strain on the gastroesophageal junction
by increased respiratory effort in SDB is hypothesized to
lead to nGER [4]. Conversely, persistent nGER seems to
be a risk factor for developing symptoms of SDB [2]. How-
ever, obesity is a significant confounder as it increases the
risk of both SDB and nGER [5].
Two different pathophysiological mechanisms have been
proposed for the GER-induced respiratory symptoms and
diseases. One involves micro-aspiration of gastric fluids
into the lungs causing irritation and inflammation, while
the second involves bronchoconstriction caused by a vagal
reflex induced by acidic reflux to the distal oesophagus
[6]. Studies on respiratory biomarkers in GER suggest
these two mechanisms are probably associated with differ-
ent extra-oesophageal manifestations [7]. For instance,
pepsin has been described as a marker of aspiration, and
neuroinflammatory markers such as neurokinin A and
substance P associated with a vagal reflex [8, 9]. Further
studies on the pathogenesis will increase our understand-
ing of the interactions between nGER, SDB and respira-
tory symptoms, which will ultimately lead to a more
appropriate treatment of these patients.
Our aim was to comprehensively investigate the associ-
ation between nGER and respiratory symptoms, exacerba-
tions of respiratory symptoms, lung function and SDB.
We used various exhaled biomarkers to study if the two
above mentioned mechanisms explained the association
between nGER and respiratory disorders, and if the two
mechanisms had different symptom profiles. We also
hypothesized that SDB might affect the association
between nGER and respiratory disorders.
Methods
This study is based on a 20 years prospective, population-
based cohort study in Reykjavik, Iceland, the European
Community Respiratory Health Survey (ECRHS, see
http://www.ecrhs.org). The study participants in ECRHS
in Iceland were first studied in 1990 [10], re-studied in
2000 [11], and for the third time in 2012, when the partici-
pants were aged 40–65 years. Among the 522 subjects
contacted in Iceland for ECHRS III, a total of 455 partici-
pated, or 87 % of those invited [12]. They participated in a
structured interview, answered questionnaires including
the Epworth sleepiness scale, underwent spirometry, mea-
surements of height and weight, gave blood samples, and
underwent a home polygraphic study. All participants
reported their medications, including proton pump inhibi-
tors (PPI), and if they used them on a regular basis or as
needed. A subgroup also underwent a 24 h oesophageal
pH-impedance measurement, the results of which have
been reported elsewhere [13].
Of the 455 participants in ECRHS III in Iceland, 82
had symptoms suggestive of nGER. These 82 subjects
were invited for a second visit in 2013, of which 71
(87 %) participated. Also, 63 age and gender paired
controls from the ECRHS III cohort without any nGER
symptoms were invited, of which 49 (78 %) participated.
BMI pairing was attempted but only partially accom-
plished due to insufficient cohort size.
During the second visit all subjects participated in a
structured medical interview, answered a modified reflux
disease questionnaire [13], were weighted again, and
examined with laryngoscopy. Exhaled breath condensate
(EBC), particles in exhaled air (PEx) [14] and blood were
sampled. Nitric oxide in exhaled air (FeNO) was mea-
sured. Height and the new weight were used to calculate
body mass index (BMI).
As those with suspected nGER were invited first, the
median time from first to second visit was 4.8 months
for the nGER group and 8.4 months for the control
group (p < 0.001).
The study was approved by the Bioethics Committee
of Iceland (National Bioethics Committee of Iceland:
VSN-11-121) and all participants signed informed
consent.
Structured medical interview
The interview was performed to collect information on
health status changes from the last visit (2012). The
interview asked specifically about changes in general
health status and in medication, as well as recent
respiratory and OSA symptoms using selected questions
from the previous visit’s questionnaire; see further details
in respective sections below.
In total, 7 cases and 7 controls reported changes in
health status since their last visit. In the case group,
health changes included diagnosis of haemochromatosis,
removal of a liver cyst, lumbago etc. In the control
group, health changes included coronary artery disease,
discus prolapse, hypothyroidism, candida oesophagitis
etc. Altogether 14 cases had any changes in their
medical treatment, among which one discontinued PPI
treatment, one started PPI treatment and 4 had changes
in PPI treatment. Among controls, 6 had changes in
their medical treatment, none of which regarded PPI.
No use of other antacid medicine was reported.
Definition of nGER
The definition of nGER was based on a modified version
of the Reflux Disease Questionnaire (RDQ) [13, 15]. The
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modification was that questions from the heartburn and
regurgitation dimensions were posed specifically for
daytime symptoms and nocturnal symptoms in the pre-
vious 4 weeks. The modified version has not been as
thoroughly validated as the original RDQ, but has been
shown to identify subjects with nGER sufficiently [13].
Those reporting any nocturnal GER symptoms on the
first (2012) and second visit (2013) were defined as
having nGER (n = 48). Those without nocturnal GER
symptoms on the first and second visit were defined as
controls (n = 42). Those with nocturnal GER symptoms
on only one of the visits were excluded (Fig. 1).
Respiratory and OSA symptoms
Participants were asked at follow-up about various
respiratory symptoms in the previous 12 months, using
questions from the main ECRHS III questionnaire
(http://www.ecrhs.org) [10]. For analysis purposes, the
symptoms were later grouped into asthma symptoms
(wheeze, chest tightness, breathlessness at rest, breath-
lessness after exercise, nocturnal cough, nocturnal at-
tacks of breathlessness) and bronchitis symptoms (cough
or phlegm without ongoing respiratory infection). An
exacerbation of respiratory symptoms was defined as a
temporary marked increase in respiratory symptoms:
cough, phlegm and shortness of breath. Frequent exacer-
bations were defined as at least two exacerbations in the
previous 12 months. Current asthma was defined as
questionnaire-reported physician diagnosed asthma as
well as either experienced asthma symptoms in the
previous 12 months and/or currently using any medicine
for asthma [16].
Symptoms of OSA were analysed at follow-up with
selected questions from a questionnaire developed by
the Sleep Apnea Global Initiative Consortium (SAGIC)
[12]. The participants were asked about sleep related
symptoms in the previous month. Specifically, the ques-
tions regarded frequency of self-reported snoring and
apneas on a five point frequency scale, and how sleepy
they felt during the day on a five point scale (Not at all,
a little bit, moderately, quite a bit, extremely). Snoring
was considered positive if reported at least three times
per week, and apneas if reported at least once per week.
Daytime sleepiness was considered present if reported as
moderate or more.
Spirometry
Results from a pre- and post-bronchodilator spirometry
done during the main ECRHS III study were used for as-
sessment of airway obstruction and reversibility. Spirometry
was performed in the same manner as in previous ECRHS
studies [11]. Forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC) was recorded and
reference values were calculated according to the NHANES
III study [17]. Reversibility test was considered positive if
FEV1 increased at least 200 ml after bronchodilation
as well as increased at least 12 % compared to before
bronchodilation.
Home polygraphic studies
Subjects were invited for a home polygraphy with a T3
device (Nox Medical, Reykjavik, Iceland), a type 3
polygraphy as previously described [12]. The polygra-
phies were scored by two trained sleep technologists.
Fig. 1 A flow diagram of selection of cases and controls. At the top are subjects at the time of first visit in the ECRHS III study, and at the bottom at
follow-up around 5–8 months later. The groups in bold were used for further analysis: Subjects who were symptomatic at baseline and follow-up
(persistent nGER), and subjects who were asymptomatic at baseline and follow-up (controls). nGER = nocturnal gastroesophageal reflux
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Polygraphies were scored in accordance with the
American Academy of Sleep Medicine 2007 manual
using the accepted hypopnea classification requiring a
≥30 % drop in respiratory flow for ≥10 s with ≥4 %
oxygen desaturation [18].
Snoring was measured using audio recordings from a
sensor on the chest. Snore events were automatically
scored using the Noxturnal 4.3 scoring algorithm, with
an absolute threshold for snore events set as audio
volume >65 dB. In comparison to manually scored snore
events, this definition has been shown to have sensitivity
and a positive predictive value of 0.79 and 0.94, respect-
ively [19]. A snore index was calculated as the number
of snores per hour of sleep.
Collection of biosamples from exhaled air
EBC samples were collected with ECoScreen II (FILT -
Lung- and Thorax Diagnostic GmbH, Germany) at -10 °C
for 15 min. Participants wore a nose-clip and used tidal
breathing. The samples collected were immediately
divided into polypropylene test tubes (Screw cap micro
tube 72.694.007, Sarstedt, Germany), 0.5 ml into each
tube. Depending on the volume collected, the number of
tubes varied from three to six. If any excess volume was
left, it was measured and then disposed. 25 μl of a mixture
of protease inhibitors was added to the first two test
tubes (cOmplete, Mini version 10; Roche Diagnostics,
Germany). Nothing was added to the third test tube.
5 μl of a 5 mg/ml solution of butylated hydroxytoluene
in ethanol was added to the fourth test tube (Sigma-
Aldrich, USA). If a fifth test tube was collected, 25 μl
of the same protease inhibitors mixture was added as
above. Other test tubes had no additives. The samples
were immediately frozen at -20 °C, and within four
hours moved to -80 °C for storage until measurements
were performed.
FeNO was measured with NIOX MINO (Aerocrine,
Sweden) according to manufacturer description (see
http://www.niox.com). Participants were allowed a max-
imum of five repetitions to perform the measurement.
However, more than one repetition was rarely needed
and never more than three repetitions.
A method to collect particles in exhaled air has recently
been established, using an instrument developed specific-
ally for this purpose (PExATM, Sahlgrenska University
Hospital, Gothenburg, Sweden) [14]. The exhaled particles
have been shown to reflect the respiratory tract lining
fluid and to origin mainly from the small airways [20].
Before sample collection start, participants breathed
filtered air for two minutes tidally to avoid contamination
of ambient particles. A specific breathing manoeuvre,
allowing for airway closure and re-opening to augment
the number of exhaled particles, was applied. In this
manoeuvre, the participants exhaled to residual volume,
held their breath for three seconds, then inhaled sharply
up to full inspiration, and finally exhaled with a velocity
between 25 and 1000 ml/s to almost full expiration. Parti-
cles were only collected from the last exhalation of this
manoeuvre. In between these breathing manoeuvres, the
participants breathed filtered air tidally for 30–60 s. The
breathing manoeuvre was repeated until 300 ng of PEx
had been collected, or until the collection had taken
30 min in total, whichever came first.
The total mass of the collected particles was calculated
based on the number and size of the particles, assuming
them to be spherical and have a density of 1000 kg/m3 [21].
The exhaled particles were collected by impaction on a
teflon filter (LCR Membrane Filter, Merck Millipore,
Germany), which was divided into two halves immediately
after sampling, and each half was stored in a polypropylene
test tube (Screw cap micro tube, Sarstedt, Germany). The
filters were immediately frozen at -20 °C, and within
four hours moved to -80 °C until measurements were
performed.
Collection of plasma samples
Plasma samples were collected from a peripheral vein in
EDTA-treated tubes. Albumin was measured directly,
but for other measurements, the samples were frozen at
-80 °C until measurements were performed.
Biomarker measurements
Plasma albumin levels were measured using a Vitros 5.1
analyser and Vitros MicroSlide method (Ortho-Clinical
Diagnostics, Rochester, USA). Albumin levels in EBC were
determined by immunoturbidometry using aVirtos 5.1 ana-
lyser and reagents from Ortho-Clinical Diagnostics. Plasma
high sensitivity C-reactive protein (hs-CRP) was mea-
sured on a Cobas 411 analyser using reagents from
Roche Diagnostics, Mannheim, Germany. Interleukin 8
(IL-8) levels in plasma and EBC samples were deter-
mined using ELISA reagents (IBL International GmbH,
Hamburg, Germany). Additionally, we performed
ELISA measurements in EBC of pepsin (Wuhan EIAAB
Science Co, Wuhan, China), 8-isoprostane (Cayman
Chemical Company, Ann Arbor, MI, USA), neurokinin
A (RayBiotech Inc, Norcross, A, USA) and substance P
(Cayman Chemical Company, Ann Arbor, MI, USA).
From the PEx samples, we registered data on exhaled
particles’ number and mass, and measured albumin and
surfactant protein A as markers of pulmonary inflam-
mation as previously described [21]. Prior to protein
assay of the PEx samples, the particles were extracted
from Teflon filters using phosphate-buffered saline
(PBS), containing 1 % bovine serum albumin (BSA), w/
v, and 0.05 % Tween-20, v/v. 140 μl of the extraction
buffer was added to each sample, followed up by
60 min shaking at 400 rpm and 37 °C at a thermomixer
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(Thermomixer comfort, Eppendorf; Eppendorf AG,
Hamburg, Germany). Surfactant protein A (SP-A) in
PEx and plasma was quantified using human SP-A
ELISA kit (BioVendor, Czech Republic) and albumin
using human albumin ELISA kit (Immunology
Consultants Laboratory, Inc., USA), according to the
manufacturer’s instructions, with small modifications.
The human albumin ELISA assay has no cross-
reactivity to bovine albumin.
When biomarkers were not measurable, because the
concentration was below the lower limit of detection,
their value was set as half the lower limit of detection
for statistical analysis.
Statistical analysis
All statistics were calculated with STATA 13.0 software,
version intercooled (Stata Corporation, College Station,
Texas). Associations and adjusted calculations were
analysed as appropriate by chi square test, Fisher’s exact
test, Wilcoxon rank-sum test, Spearman’s rank-order
correlation and linear regression. A p-value of < 0.05 was
considered statistically significant. As the aim was to
give a comprehensive view of the complex association
between nGER, respiratory symptoms and sleep-
disordered breathing, no specific outcome variables were
described as main outcomes.
Sensitivity analysis was done by adjusting for BMI as
pairing was only partially accomplished. For parametric
tests, a multiple linear regression was used. For categor-
ical and non-parametric tests, calculations were redone
with above mentioned tests, while either adjusting for
BMI, or excluding those with BMI 35 or over when
adjustment calculations were not applicable (one subject
from control group and 7 subjects from nGER group
excluded) (mean BMI ± SD: control group 26.9 ± 3.7;
nGER group 27.6 ± 2.9, p = 0.38).
Results
No difference was found between the two study groups
in terms of age, gender, smoking status or incidence of
arterial hypertension or diabetes (Table 1). The nGER
group had a higher BMI, although statistically non-
significant. Current asthma was significantly more
common in the nGER group (27 % vs 7 %, p = 0.01).
Respiratory symptoms and spirometry
Symptoms of asthma and bronchitis were significantly
more common among nGER subjects. Specifically,
symptoms such as chest tightness, breathlessness, cough
and phlegm were more common among nGER subjects
(Table 2). Exacerbations of respiratory symptoms were
significantly more common among nGER subjects. This
difference was more pronounced when looking at
frequent exacerbations (Fig. 2).
No significant differences were observed in the post
bronchodilator forced expiratory volume in one second
(FEV1), forced vital capacity (FVC), FEV1/FVC or
reversibility.
BMI was positively associated with more exacerbations of
respiratory symptoms among those with nGER (p = 0.046).
Other findings were not affected by adjusting for BMI.
Table 1 Subject characteristics
No nGER
(n = 42)
nGER
(n = 48)
p-value
Age (mean ± SD) 56.4 ± 7.0 55.8 ± 6.7 0.70
Female gender 48 % 46 % 0.87
BMI (median (IQR)) 25.9 (24.5–29.7) 28.1 (26.4–31.0) 0.07
Arterial hypertension 31 % 35 % 0.65
Diabetes 2.4 % 4.2 % 0.55
Ischaemic heart disease 2.4 % 4.2 % 0.55
Heart failure 0 2.1 % 0.53
Stroke 2.4 % 4.2 % 0.55
Smoking status:
- Non-smoker 45 % 33 % ref.
- Former smoker 45 % 46 % 0.49
- Current smoker 10 % 21 % 0.10
Current asthma 7.1 % 27.1 % 0.01
- On any asthma medication 7.1 % 12.5 % 0.49
Regular use of PPI 0 29 % <0.01
SD standard deviation, IQR interquartile range, PPI Proton Pump Inhibitor,
ref reference
Table 2 Respiratory symptoms and nocturnal gastroesophageal
reflux
No nGER
(n = 42)
nGER
(n = 48)
p-value
Any asthma symptom: 28.6 % 54.2 % 0.01
Wheeze 16.7 % 27.1 % 0.24
- with breathlessness 4.8 % 14.6 % 0.12
- without cold 14.3 % 22.9 % 0.30
Chest tightness 0.0 % 14.6 % 0.01
Breathlessness at rest 0.0 % 14.6 % 0.01
Breathlessness after exercise 9.5 % 31.3 % 0.01
Nocturnal attacks of breathlessness 0.0 % 8.3 % 0.06
Nocturnal cough 14.3 % 29.2 % 0.09
Any bronchitis symptom: 26.2 % 60.4 % <0.01
Chronic morning cough 9.5 % 29.2 % 0.02
Chronic cough 14.3 % 33.3 % 0.04
- Coughing at least 3mo/y 11.9 % 27.7 % 0.07
Chronic morning phlegm 19.1 % 39.6 % 0.03
Chronic phlegm 9.5 % 20.8 % 0.14
- Phlegm at least 3mo/y 18.0 % 37.8 % 0.05
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Sleep-disordered breathing
Three subjects in the control group had a previously
diagnosed OSA, whereof two were currently on treat-
ment with positive airway pressure. Two subjects in the
nGER group had a previously diagnosed OSA, whereof
one was currently on treatment with positive airway
pressure.
Reported snoring was more common among subjects
with nGER, as well as daytime sleepiness. Apnea-
hypopnea index (AHI) was significantly higher among
nGER subjects compared with controls, as well as audio
measured snoring (Table 3).
Snoring was positively associated with exacerbations of
respiratory symptoms among those with nGER, but not
among those without nGER (Fig. 3). Furthermore,
among those with nGER, snoring was only significantly
associated with exacerbations among subjects with
measurable pepsin in EBC (non-measurable pepsin in
EBC: p = 0.33, measurable pepsin in EBC: p = 0.03).
After adjusting for BMI, AHI was no longer associ-
ated with nGER, but audio measured snoring was still
significantly associated with nGER after adjusting for
BMI. Other findings were not affected by adjusting
for BMI.
Biomarker analysis
Pepsin levels were higher in the nGER group. Substance
P and 8-isoprostane were also higher in EBC among
subjects with nGER than those without nGER. In PEx,
both albumin and surfactant protein A (SP-A) were
lower in subjects with nGER than in those without. In
plasma samples, no difference was found in SP-A, hs-
CRP or IL-8 concentrations between nGER subjects and
controls (Table 4).
In the nGER group, IL-8 in plasma was signifi-
cantly higher among those with exacerbations of
respiratory symptoms than in those without exacer-
bations (median (IQR): 1.6 pg/ml (1.2–3.1) vs.
0.2 pg/ml (0.2–2.3), p = 0.03) (Fig. 4a). In the nGER
group, substance P was higher among those with
nocturnal cough than those without nocturnal cough
(708 pg/ml (597–793) vs. 808 pg/ml (732–900), p = 0.03)
Fig. 2 Exacerbations of respiratory symptoms in the previous 12 months among subjects with or without nGER. * p = 0.02 by chi square test
Table 3 Symptoms and signs of obstructive sleep apnea and
nocturnal gastroesophageal reflux
No nGER
(n = 42)
nGER
(n = 48)
p-value
Self-reported symptoms:
Snoring ≥3 x week 23.8 % 44.7 % 0.04
Witnessed apneas ≥1 x week 2.4 % 12.5 % 0.08
Daytime sleepiness 9.8 % 46.8 % <0.001
Epworth sleepiness scale >10 22 % 39 % 0.08
Epworth sleepiness scale
(mean ± SD)
6.6 ± 4.0 8.2 ± 5.4 0.12
Polygraphy results:
Moderate/severe OSA 10.5 % 26.2 % 0.07
AHI (median (IQR)) 1.9
(0.5–8.0)
4.8
(1.4–16.2)
0.03
Snore index (snores per hour
of sleep) (median (IQR))
67
(32–182)
177
(79–281)
0.004
Snore groups: 0.01
Snore index≤ 100 61 % 26 %
Snore index 101–250 24 % 45 %
Snore index > 250 16 % 29 %
SD standard deviation, OSA obstructive sleep apnea, AHI apnea-hypopnea
index, IQR interquartile range
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(Fig. 4b). No other significant differences were found in
biomarkers in the nGER group in relation to exacerba-
tions or respiratory symptoms.
The biomarker findings were not affected by adjusting
for BMI.
Discussion
In a general population sample, nGER was signifi-
cantly associated with symptoms of asthma and
bronchitis, as well as exacerbations of respiratory
symptoms. Symptoms of SDB were also more common
among those with nGER, and they had a higher num-
ber of measured events on a polygraphy. Participants
with nGER had higher pepsin and higher inflammatory
biomarkers in exhaled air. The biomarker findings
support both theories on micro-aspiration of gastric
fluids (increased pepsin and 8-isoprostane in EBC)
and neurogenic inflammation through a vagal reflex
(increased substance P in EBC) as causes of nGER
related respiratory symptoms.
Respiratory symptoms
The positive associations between nGER and respira-
tory symptoms as well as exacerbations of respiratory
symptoms in the current study are in accordance with
previous studies that have shown an association
between GER and respiratory symptoms, COPD and
asthma exacerbations [2, 22, 23]. Our study adds that
the effect of nGER on the airways might be mediated
by pepsin, 8-isoprostane and substance P. BMI had
little effect on these results. Additionally, adjusting
for both smoking and BMI did not significantly affect
the results (data not shown).
We found IL-8 in plasma to be elevated among par-
ticipants with both nGER and exacerbations. In asth-
matic children, IL-8 has been found to be increased in
bronchoalveolar lavage (BAL) only among those with
GER [24]. Additionally, a correlation between IL-8 and
bile acids in BAL has been demonstrated in lung
Fig. 3 A positive association was found between snoring and exacerbations of respiratory symptoms among subjects with nGER, but not among
subjects without nGER. * p = 0.03 by linear regression
Table 4 Biomarkers in subject samples, measured in exhaled air,
exhaled breath condensate, particles in exhaled air, and plasma
No nGER
(n = 42)
nGER
(n = 48)
p-value
Exhaled air:
FeNO (ppb) 15 (13–20) 17 (11–25) 0.48
EBC:
Substance P (pg/ml) 623 (562–676) 741 (626–821) <0.001
Neurokinin A (% detected) 17 % 30 % 0.13
Pepsin (ng/ml) 0.8 (0.8–3.6) 2.5 (0.8–5.8) 0.03
IL-8 EBC (% detected) 12 % 19 % 0.37
8-isoprostane (pg/ml) 2.6 (2.2–2.9) 3.0 (2.7–3.9) 0.002
PEx:
Albumin (mg/ga) 73 (57–91) 48 (31–69) <0.001
SP-A (mg/ga) 38 (31–43) 25 (20–35) <0.001
Albumin/SP-A (ratio) 1.92 (1.50–2.64) 1.74 (1.26–2.95) 0.79
Plasma:
hs-CRP (mg/l) 1.05 (0.68–2.26) 1.08 (0.62–1.94) 0.96
IL-8 plasma (% detected) 57 % 52 % 0.63
SP-A (ng/ml) 34.7 (29.8–48.6) 35.6 (27.6–47.0) 0.81
Values presented as “median (interquartile range)” unless otherwise stated
SP-A Surfactant protein A, IL-8 Interleukin 8, FeNO Fraction of exhaled nitric
oxide, hs-CRP High sensitivity C-reactive protein, ppb parts per billion
aMeasured as mg of protein per gram of exhaled particles
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transplanted patients who developed bronchiolitis
obliterans syndrome [25]. In the current study, it is
possible that the elevated IL-8 concentration was more
related to frequent exacerbations in general, as these
subjects were almost exclusively in the nGER group.
However, as the previously mentioned studies found
IL-8 to be increased specifically in GER in two different
patient groups, we suspect this rather reflects the air-
way inflammation related to GER. This data therefore
suggests a specific role of IL-8 in neutrophil recruitment
in GER related respiratory conditions, related to micro-
aspiration of gastric contents.
In our study, the oxidative stress biomarker 8-
isoprostane was increased in EBC among those with
nGER, as has previously been shown for GER in subjects
with asthma [26]. This might reflect that persistent
nGER leads to oxidative stress and inflammation of the
airways, likely through direct effects of gastric contents
on the airway epithelium.
We found significantly higher levels of the neuroinflam-
matory marker substance P in EBC among those with
nGER, especially among those with nocturnal cough,
suggestive of a neural mediated association between nGER
and nocturnal cough. This finding is in accordance with
Fig. 4 a Interleukin 8 levels in plasma among nGER subjects with or without exacerbations of respiratory symptoms. The transverse line
represents median value. b Substance P levels in exhaled breath condensate among subjects with nGER with or without nocturnal
cough. The transverse line represents median value. P-values calculated with Wilcoxon rank-sum test
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previous studies on neuroinflammatory markers in GER
and chronic cough [27]. Indeed, studies on distal
oesophageal acid perfusion show a significant stimulus of
the vagal nerve, with resulting bronchoconstriction and
heart rate variation [28]. In support of the so-called reflex
theory, we hypothesize that GER-induced vagal stimula-
tion can cause neurogenic inflammation in the lungs, with
cough being the main resulting symptom. Further studies
are needed to evaluate this hypothesis.
Albumin and SP-A levels were lower in PEx among
those with nGER, indicating an effect on small airways.
The reduced proportion of surfactant protein A in the
small airways lining fluid is likely to impact on surfac-
tant function and host defence [29]. In turn, this might
explain the association between nGER and exacerbations
of respiratory symptoms. These findings suggest that
nGER not only affects the proximal airways, but also the
distal airways.
Of note, plasma hs-CRP was not associated with
nGER, suggesting that the elevated inflammatory
markers seen in EBC and PEx represented a local effect
of nGER without a systemic effect.
Sleep-disordered breathing
In the present study, nGER was associated with SDB
and SDB-related symptoms. Previously, persistent nGER
has been shown to increase the new onset of SDB symp-
toms, and SDB treatment with continuous positive
airway pressure reduces nGER [2, 30]. SDB can likely
lead to nGER through strain of the lower oesophageal
sphincter, and nGER worsen SDB through increased
proximal airway inflammation, resulting in a negative
spiral [31, 32]. Of the objectively measured markers for
SDB, we found the strongest association between nGER
and audio measured snoring, especially after adjusting
for BMI. This association has been reported but is much
less studied than the association with AHI [33]. Interest-
ingly, AHI has been found to correlate poorly with
patient-centred outcomes such as quality of life [34].
Also, snoring has been associated with excessive
daytime sleepiness and daytime fatigue independently
of AHI [35].
We found that nGER and snoring had a synergistic
effect in their association to exacerbations of respira-
tory symptoms. Previous studies have found such
exacerbations to be associated with nGER, as well as
SDB, but to our knowledge this synergistic effect has
not been described before [22, 36]. As this effect
was more pronounced among those with measurable
pepsin in EBC, we hypothesize that SDB-associated
nGER causes exacerbations of respiratory symptoms
by micro-aspirations of gastric contents, but further
research is needed.
Strengths and limitations
The strengths of this study lie in the detailed analysis
of respiratory biomarkers and home polygraphic
studies performed in a well-defined study population
based on a random general population sample. How-
ever, there were also certain limitations to this study.
First, given the background of the study population,
the number of severely symptomatic cases was low,
resulting in a generally mild disease burden. Conse-
quently, biomarkers may have been less affected than
in a group with more severe disease, increasing the
risk for false negatives. Second, biosamples were
collected at different time points during the day, and
therefore the biomarker measurements could be
affected by circadian variability. However, as partici-
pants’ visits were similarly spread over time of day,
circadian variability was unlikely to affect our results.
Third, there is some uncertainty regarding where the
biomarkers measured in EBC are derived from, and
the water-vapour dilution of these samples is difficult
to adjust for. Additionally, many of the biomarkers in
EBC were near or below the lower limit of detection,
making the measurements somewhat unreliable. How-
ever, the biomarkers which were well above the detec-
tion limit in EBC such as pepsin, substance P and 8-
isoprostane differed clearly between the nGER and
control group.
Conclusions
We found that nocturnal gastroesophageal reflux associ-
ates with asthma and bronchitis symptoms as well as
exacerbations of respiratory symptoms. The association is
further supported by significant changes in airway inflam-
matory biomarkers, both in large and small airways. On
the other hand, those with nocturnal gastroesophageal
reflux and nocturnal cough had mostly increased signs of
neurogenic inflammation. This indicated that the two
hypothesized mechanisms of micro-aspiration and neuro-
genic inflammation might both be true, but associated
with somewhat different symptoms. Snoring was also
associated with nocturnal gastroesophageal reflux, and
when combined with nocturnal gastroesophageal reflux, it
strengthened the association with exacerbations of
respiratory symptoms. This association between nocturnal
gastroesophageal reflux and respiratory symptoms, where
micro-aspiration, neurogenic inflammation and sleep-
disordered breathing seem to be the responsible mecha-
nisms, needs to be studied further.
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